Developing effective personalized treatments for neuropsychiatric disorders based on individual brain biology.
The current approach to psychiatric treatment is a trial-and-error crisis — characterized by high failure rates, ineffective one-size-fits-all treatment, lengthy diagnosis processes, and limited new drug development.
This broken system stems from a drug development process that prioritizes biochemical assays, animal models, and large-scale clinical trials, failing to account for the complexity and uniqueness of individual human brains.
NeuTherX is building the platform to change this — starting from the patient's own biology.
Current psychiatric medications fail the majority of patients on first prescription.
Treatment ignores the complexity and uniqueness of individual brain biology.
Patients endure frustrating, drawn-out processes before finding effective treatment.
Poor understanding of disease mechanisms hinders new therapeutic breakthroughs.
Brain organoid models derived from each patient's somatic cells, from a small sample of their blood. These personalized models replicate the patient's biology and genetics, recapitulating key characteristics of their brain disorder.
Deep biological analyses including massively parallel protein expression profiling, single-cell RNA Seq, high content imaging for cellular morphology, and electrophysiology to measure electrical activity and neuronal communication.
Vast quantities of phenotyping data integrated with genetic, genomic, and omics databases, medical research publications, and each patient's medical records for a comprehensive biological picture.
Signals reflecting the precise nature of a brain disorder are extracted from massive data collections using an advanced artificial intelligence platform to identify actionable therapeutic targets.
NeuTherX's platform harnesses brain organoid technology to transform diagnosis, understanding, and treatment of complex brain disorders.
By analyzing comprehensive biological signatures of patient-derived organoids, NeuTherX identifies the optimal drugs to restore brain function to a normal state — treatment that is both effective and tailored to the individual's unique needs.
High-throughput capabilities and diverse data integration provide a powerful tool for identifying novel therapeutic targets and developing new drugs — potentially leading to breakthroughs across neurological and psychiatric disorders.
The ability to predict individual drug responses using organoid models streamlines clinical trials, reducing costs and accelerating the delivery of innovative treatments to patients in need.
Biomedical scientist focused on human disease and aging. Former professor at SUNY Upstate Medical University (Depts. of Medicine, Biochemistry & Molecular Biology). Co-founder and former CEO of NanoPore Bio. PhD in Biological Sciences from Carnegie Mellon University.
Neurobiologist with extensive experience in mammalian pluripotent and neural stem cell research, including patient-derived iPSC brain organoids. Initiated one of India's first human embryonic stem cell research programs. PhD in Biological Sciences from Carnegie Mellon University.
Faculty at UC Irvine School of Medicine. Pioneer in mechanobiology, establishing molecular mechanisms of ion channel regulation. PhD in Biophysics from UC Berkeley. Postdoctoral research at Harvard Medical School and UC Irvine. Integrates ion channel biophysics, stem cell biology, and bioengineering.
NeuTherX is filing a provisional patent covering proprietary methods underlying our platform, with additional patents planned as our technology develops.